ANG Lifesciences
ANGLIFESCIENCESINDIALTD NSE
ANG Lifesciences
HealthcareNSE: ANGLIFESCIENCESINDIALTD BSE: ANG Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹46.80 Cr
Volatility
Moderate
P/E Ratio
-3.5
EBITDA
₹0.70 Cr
Return on Equity
-19.4%
Debt to Equity
1.49
Book Value
₹40.5
52W High
₹49.69
52W Low
₹17.63
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Stock is trading at 0.89 times its book value
Weaknesses
5- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -9.66% over past five years.
- Company has a low return on equity of -15.1% over last 3 years.
- Promoters have pledged 44.9% of their holding.
- Company has high debtors of 267 days.
Growth Rate
Revenue Growth
-2.12% higher than
3Y
Net Income Growth
4.92% lower than
3Y
Cash Flow Change
97.26% higher than
3Y
ROE
45.86% higher than
3Y
ROCE
—
EBITDA Margin (Avg.)
-388% lower than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 56.46 | 33.26 | 18.55 | 37.84 | 18.41 | 32.88 | 24.73 | 16.82 | 24.6 | 26.05 | 18.73 | 23.5 | 15.3 |
| Expenses | 49.92 | 31.6 | 20.46 | 34.48 | 20.12 | 30.6 | 26.88 | 17.52 | 23.95 | 25.97 | 21.41 | 20.82 | 17.25 |
| Operating Profit | 6.54 | 1.66 | -1.91 | 3.36 | -1.71 | 2.28 | -2.15 | -0.7 | 0.65 | 0.08 | -2.68 | 2.68 | -1.95 |
| OPM % | 11.58% | 4.99% | -10.3% | 8.88% | -9.29% | 6.93% | -8.69% | -4.16% | 2.64% | 0.31% | -14.31% | 11.4% | -12.75% |
| Other Income | 0.32 | 0.22 | -0.03 | -1.55 | 1.28 | 0.35 | -0.27 | 0.65 | 0.09 | 0.12 | 0.16 | 0.17 | 0.11 |
| Interest | 2.31 | 2.29 | 2.51 | 3.84 | 2.08 | 2.18 | 2 | 2.42 | 1.94 | 1.89 | 1.93 | 2.18 | 2.24 |
| Depreciation | 2.19 | 2.22 | 1.91 | 2.05 | 1.63 | 1.74 | 1.96 | 1.42 | 1.53 | 1.52 | 1.51 | 1.77 | 1.5 |
| PBT | 2.36 | -2.63 | -6.36 | -4.08 | -4.14 | -1.29 | -6.38 | -3.89 | -2.73 | -3.21 | -5.96 | -1.1 | -5.58 |
| Tax % | 25.85% | -12.17% | -6.92% | -10.54% | -25.85% | 62.02% | -18.65% | -47.04% | -26.74% | -8.41% | -20.3% | 25.45% | -24.01% |
| Net Profit | 1.75 | -2.32 | -5.93 | -3.65 | -3.07 | -2.09 | -5.19 | -2.06 | -2.01 | -2.95 | -4.75 | -1.38 | -4.24 |
| EPS in Rs | 1.34 | -1.78 | -4.54 | -2.8 | -2.35 | -1.6 | -3.97 | -1.58 | -1.54 | -2.26 | -3.64 | -1.06 | -3.25 |
Profit & Loss
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 154 | 354 | 220 | 145 | 93 | 93 | 84 |
| Expenses | 140 | 286 | 205 | 135 | 94 | 92 | 85 |
| Operating Profit | 14 | 68 | 15 | 10 | -1 | 1 | -2 |
| OPM % | 9% | 19% | 7% | 7% | -1.6% | 0.8% | -2.2% |
| Other Income | 1 | 1 | 10 | -1 | 2 | 1 | 1 |
| Interest | 4 | 9 | 12 | 11 | 9 | 8 | 8 |
| Depreciation | 1 | 6 | 9 | 8 | 7 | 6 | 6 |
| PBT | 10 | 54 | 3 | -11 | -16 | -13 | -16 |
| Tax % | 31% | 25% | 110% | -5% | -21% | -15% | — |
| Net Profit | 7 | 40 | 0 | -10 | -12 | -11 | -13 |
| EPS in Rs | 5.26 | 31.02 | -0.2 | -7.77 | -9.5 | -8.49 | -10.21 |
| Div. Payout % | 0% | 3% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity Capital | — | 10 | 13 | 13 | 13 | 13 |
| Reserves | — | 73 | 73 | 63 | 51 | 40 |
| Borrowings | — | 77 | 71 | 73 | 83 | 79 |
| Other Liabilities | — | 130 | 119 | 92 | 82 | 77 |
| Total Liabilities | — | 290 | 276 | 241 | 230 | 209 |
| Fixed Assets | — | 93 | 88 | 58 | 57 | 51 |
| CWIP | — | 0 | 0 | 0 | 0 | 0 |
| Investments | — | 0 | 0 | 0 | 0 | 0 |
| Other Assets | — | 198 | 188 | 183 | 172 | 158 |
| Total Assets | — | 290 | 276 | 241 | 230 | 209 |
Cash Flow
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | — | 25 | 26 | -9 | 0 | 11 |
| Investing | — | -44 | -9 | 20 | -2 | 1 |
| Financing | — | 20 | -17 | -10 | 2 | -12 |
| Net Cash Flow | — | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | — | -17 | 16 | 9 | -4 | 11 |
| CFO/OP | — | 37 | 202 | 39 | -272 | 1,559 |
Ratios
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor Days | — | 105 | 138 | 184 | 262 | 267 |
| Inventory Days | — | 59 | 118 | 183 | 331 | 279 |
| Days Payable | — | 113 | 165 | 254 | 405 | 317 |
| Cash Conversion Cycle | — | 51 | 91 | 113 | 189 | 229 |
| Working Capital Days | — | 20 | 24 | 58 | 55 | -30 |
| ROCE % | — | — | 9% | 1% | -4% | -4% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view ANG Lifesciences insights
59 extracted metrics + investor summaries across FY13–FY26.
Documents
1
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
17 Apr - Company confirms SEBI large corporate borrowing disclosure is not applicable for FY 2025-26. 17 Apr - Company confirms SEBI large corporate borrowing disclosure is not applicable for FY 2025-26.
3
Clarification On Price Movement In Shares
10 Apr - Company clarified recent price movement, citing no new price-sensitive disclosures. 10 Apr - Company clarified recent price movement, citing no new price-sensitive disclosures.
4
Clarification sought from ANG Lifesciences India Ltd
10 Apr - Exchange has sought clarification from ANG Lifesciences India Ltd on April 9, 2026 with reference to significant movement in price, in order to ensure that … 10 Apr - Exchange has sought clarification from ANG Lifesciences India Ltd on April 9, 2026 with reference to significant movement in price, in order to ensure that …
1
Board Meeting Outcome for Board Meeting Outcome For Board Meeting Outcome For Intimation Of AGM 7 Sept 2026
Outcome
Frequently Asked Questions about ANG Lifesciences
What does ANG Lifesciences India Ltd do?
Incorporated in 2006, ANG Lifesciences
India Ltd is in the business of pharmaceuticals products & formulations, and packaging and printing.[1]
Where is ANG Lifesciences India Ltd (540694) listed?
ANG Lifesciences India Ltd trades as ANGLIFESCIENCESINDIALTD on the NSE and under code ANG on the BSE.
Which sector does ANG Lifesciences India Ltd belong to?
ANG Lifesciences India Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of ANG Lifesciences India Ltd?
ANG Lifesciences India Ltd has a market capitalisation of ₹46.8 Cr, which places it in the Small Cap band.
What is the PE ratio of ANG Lifesciences India Ltd?
ANG Lifesciences India Ltd trades at a PE ratio of -3.50, against a book value of ₹40.5 per share.
What is the 52-week high and low of ANG Lifesciences India Ltd?
Over the last 52 weeks ANG Lifesciences India Ltd has traded between ₹17.63 and ₹49.69.
Does ANG Lifesciences India Ltd pay dividends?
ANG Lifesciences India Ltd has a dividend yield of 2.79%.
What is the Return on Equity (ROE) of ANG Lifesciences India Ltd?
ANG Lifesciences India Ltd reported a return on equity of -19.40%. Its debt-to-equity ratio is 1.49.
Company Information
Incorporated in 2006, ANG Lifesciences India Ltd is in the business of pharmaceuticals products & formulations, and packaging and printing.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/540694.md for ANG Lifesciences India Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.